INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT
Pomerantz LLP is investigating potential securities fraud claims against EyePoint, Inc. following the company's announcement on August 17, 2026, that its DURAVYU drug failed to meet primary endpoints in the LUGANO Phase 3 clinical trial for wet AMD treatment. The failure to demonstrate superiority over Regeneron's Eylea resulted in a 66.98% stock price decline, falling from approximately $14.75 to $4.87 per share.